Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Profound Medical Corp. - common stock (NQ:PROF)

6.850 +0.070 (+1.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 33,766
Open 6.700
Bid (Size) 2.750 (200)
Ask (Size) 7.200 (100)
Prev. Close 6.780
Today's Range 6.637 - 6.970
52wk Range 3.760 - 8.950
Shares Outstanding 20,208,948
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026
From Profound Medical Corp.
Via GlobeNewswire

Performance

YTD
-10.6%
-10.6%
1 Month
+4.3%
+4.3%
3 Month
+3.0%
+3.0%
6 Month
-16.7%
-16.7%
1 Year
+20.3%
+20.3%

More News

Read More
News headline image
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Profound Medical Reports Strong First Quarter 2026 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
From Pomerantz LLP
Via GlobeNewswire
News headline image
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
From Profound Medical Corp.
Via GlobeNewswire
News headline image
CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
From Profound Medical Corp.
Via GlobeNewswire
Here are the top movers in Friday's session. ↗
Via Chartmill
News headline image
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease
From Profound Medical Corp.
Via GlobeNewswire
News headline image
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Announces Upcoming Investor Events
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal
From Profound Medical Corp.
Via GlobeNewswire
InvestorNewsBreaks – Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) Closes $36 Million Registered Direct Offering
Via Investor Brand Network
News headline image
Profound Medical Corp. Announces Closing of Private Placement
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Corp. Announces Upsize of Private Placement
From Profound Medical Corp.
Via GlobeNewswire

Frequently Asked Questions

Is Profound Medical Corp. - common stock publicly traded?
Yes, Profound Medical Corp. - common stock is publicly traded.
What exchange does Profound Medical Corp. - common stock trade on?
Profound Medical Corp. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Profound Medical Corp. - common stock?
The ticker symbol for Profound Medical Corp. - common stock is PROF on the Nasdaq Stock Market
What is the current price of Profound Medical Corp. - common stock?
The current price of Profound Medical Corp. - common stock is 6.850
When was Profound Medical Corp. - common stock last traded?
The last trade of Profound Medical Corp. - common stock was at 07/17/26 04:00 PM ET
What is the market capitalization of Profound Medical Corp. - common stock?
The market capitalization of Profound Medical Corp. - common stock is 138.43M
How many shares of Profound Medical Corp. - common stock are outstanding?
Profound Medical Corp. - common stock has 138M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.